PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
3.86%
Operating income growth of 3.86% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
-1.47%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
12.77%
EPS growth of 12.77% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
13.49%
Diluted EPS growth of 13.49% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
16.41%
Share change of 16.41% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
17.29%
Diluted share change of 17.29% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
23.86%
OCF growth of 23.86% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
23.57%
FCF growth of 23.57% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-19211.55%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-43.46%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-15978.83%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-50766.69%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
48.21%
3Y net income/share CAGR > 1.5x Healthcare median of 2.50%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
19776.75%
Equity/share CAGR of 19776.75% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
4394.26%
5Y equity/share CAGR > 1.5x Healthcare median of 8.45%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
625.15%
3Y equity/share CAGR > 1.5x Healthcare median of 9.57%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Asset growth of 30.51% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
8.68%
BV/share growth of 8.68% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
108.24%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.